Breaking News Instant updates and real-time market news.

TSLA

Tesla

$334.80

-12.8 (-3.68%)

12:04
08/15/18
08/15
12:04
08/15/18
12:04

Silver Lake would like to participate in Tesla deal, DealBook says

Silver Lake, which previously teamed up with Michael Dell to help take Dell Inc. private, is now working with Tesla founder and CEO Elon Musk, The New York Times previously reported, citing people with direct knowledge of the matter. Silver Lake is not being paid for its role, but instead hopes to participate in whatever deal comes together, The Times' DealBook said in a report published earlier this morning. Reference Link

  • 29

    Oct

TSLA Tesla
$334.80

-12.8 (-3.68%)

08/08/18
BARD
08/08/18
NO CHANGE
Target $411
BARD
Outperform
Tesla $420 buyout price mentioned by Musk too low, says Baird
Baird analyst Ben Kallo believes the Tesla buyout price of $420 mentioned by Elon Musk is too low. He expects the shares to trade above that mark as investors will demand a higher premium, which will coincide with short covering. Kallo reiterated his Outperform rating and $411 price target on Tesla shares.
08/08/18
RBCM
08/08/18
NO CHANGE
Target $110
RBCM
Outperform
RBC Capital revisits idea of Celgene going private after Tesla proposal
Following yesterday's news that Tesla (TSLA) CEO Elon Musk would like to see his company go private, RBC analyst Brian Abrahams revisited his prior analysis of whether Celgene (CELG) should go private in order to better capture the medium-term value of future Revlimid cash flows not being appreciated by public markets and avoid volatility as it transitions to a post-Revlimid business model. Though acknowledging that the two companies are in completely different industries, he thinks the example of Musk shows that performing such a transaction on a large company "may not be completely unrealistic," Abrahams said. Such an LBO, or perhaps more likely an acquisition by a larger pharmaceutical company, could possibly help capture more value from Celgene's commercial and pipeline products, concludes Abrahams, who has an Outperform rating and $110 price target on Celgene shares.
08/08/18
08/08/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. REACTIONS TO TESLA'S TALK OF GOING PRIVATE: Jefferies analyst Philippe Houchois raised his price target for Tesla (TSLA) to $360 from $250 after CEO Elon Musk suggested taking the company private. Going private "feels like the right thing to do," Houchois said. "Distraction or not, the move feels right even if Musk is downplaying how supportive public markets have been," the analyst adds. However, with Tesla unable to take on more debt, Houchois wondered who may fund the potential deal and end up as a new large shareholder. While Morgan Stanley analyst Adam Jonas sympathizes with Elon Musk's argument that Tesla could be better off as a private company, he questioned the feasibility of Musk actually being able to achieve that goal. Taking the company private would assume either that the company is on the verge of generating self-sustaining cash flows or that it can tap into a range of strategic sources of capital not previously at its disposal, said Jonas, who sees strategic value at Tesla but thinks the "LBO math required to support [a price of] $420 is extremely aggressive." MORGAN STANLEY SAYS SOUTHWEST A GOOD FIT FOR BERKSHIRE: Morgan Stanley analyst Kai Pan noted that Berkshire Hathaway (BRK.A) has shifted tone in recent years and become a top three shareholder of the "Big Four" U.S. airlines, including Southwest (LUV). Media reports from Forbes, CNN and others have discussed a possible acquisition by Berkshire of the airline, added Pan. He analyzed a theoretical acquisition and came to the conclusion that Southwest could be a strategic fit for Berkshire and the advantages could also be compelling for the airline. Pan estimates Berkshire could pay a 20-40% premium, or $70-80 per share for Southwest, in such a hypothetical takeover situation. Pan has an Overweight rating and $67 price target on Southwest shares. BARCLAYS POSITIVE ON SNAP GUIDANCE CHANGE: Barclays analyst Ross Sandler views Snap's (SNAP) Q2 results as a "mixed bag," with daily active users 2M below his estimate and revenue $20M above his estimate. More importantly, the change in approach towards guidance is "very welcomed and should help to reduce some of the volatility going forward," Sandler said. He believes this is a "big positive for long-term holders looking to get involved." The analyst kept an Overweight rating on Snap with a $16 price target. WAINWRIGHT SAYS INSMED LIKELY TO BE ACQUIRED: H.C. Wainwright analyst Andrew Fein raised his price target for Insmed (INSM) to $43 from $35 following the 12-2 FDA panel vote in favor of ALIS in refractory nontuberculous mycobacterial patients. Insmed is now likely to be acquired as ALIS "fits well within the pipeline of a number of larger companies," Fein said.
08/10/18
MSCO
08/10/18
NO CHANGE
Target $291
MSCO
Equal Weight
Morgan Stanley says Tesla LBO doesn't seem feasible, equity buyout might be
Morgan Stanley analyst Adam Jonas said a leveraged buyout, or LBO, of Tesla does not appear to be feasible, even with less than $10B of incremental debt. However, he believes Tesla could consider an auction for its shares in the private equity market, financed by existing shareholders, new strategic investors, the possible divestiture of assets such as Tesla's autonomous and shared mobility assets and "possibly some help from SpaceX." However, Jonas notes that he has no knowledge of an equity buyout, or EBO, being considered by the company. He maintains an Equal Weight rating and $291 price target on Tesla shares.

TODAY'S FREE FLY STORIES

TGTX

TG Therapeutics

$9.25

0.2 (2.21%)

07:33
09/25/18
09/25
07:33
09/25/18
07:33
Hot Stocks
Breaking Hot Stocks news story on TG Therapeutics »

TG Therapeutics trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ARAY

Accuray

$4.03

-0.125 (-3.01%)

07:33
09/25/18
09/25
07:33
09/25/18
07:33
Hot Stocks
Accuray publishes data from two studies on protocols using CyberKnife System »

Accuray announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYND

Wyndham Destinations

$42.48

-1.46 (-3.32%)

07:30
09/25/18
09/25
07:30
09/25/18
07:30
Conference/Events
Wyndham Destinations management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

RAD

Rite Aid

$1.24

-0.025 (-1.98%)

, BK

BNY Mellon

$52.36

-0.9 (-1.69%)

07:30
09/25/18
09/25
07:30
09/25/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

RAD

Rite Aid

$1.24

-0.025 (-1.98%)

BK

BNY Mellon

$52.36

-0.9 (-1.69%)

HUN

Huntsman

$28.20

-0.73 (-2.52%)

JBL

Jabil

$30.08

0.22 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 27

    Sep

  • 27

    Sep

  • 27

    Sep

  • 01

    Oct

  • 09

    Oct

  • 18

    Oct

  • 13

    Nov

  • 13

    Nov

RETA

Reata Pharmaceuticals

$90.96

3.4 (3.88%)

07:30
09/25/18
09/25
07:30
09/25/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Reata Pharmaceuticals »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

CACI

CACI

$188.35

2 (1.07%)

, SAIC

SAIC

$78.88

-0.59 (-0.74%)

07:29
09/25/18
09/25
07:29
09/25/18
07:29
Downgrade
CACI, SAIC, Engility rating change  »

CACI downgraded to Hold…

CACI

CACI

$188.35

2 (1.07%)

SAIC

SAIC

$78.88

-0.59 (-0.74%)

EGL

Engility

$35.14

-0.12 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OLED

Universal Display

$121.65

0.25 (0.21%)

07:28
09/25/18
09/25
07:28
09/25/18
07:28
Recommendations
Universal Display analyst commentary  »

Universal Display price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

MTDR

Matador

$33.20

0.66 (2.03%)

07:27
09/25/18
09/25
07:27
09/25/18
07:27
Downgrade
Matador rating change  »

Matador downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$165.40

2.5 (1.53%)

07:27
09/25/18
09/25
07:27
09/25/18
07:27
Recommendations
Facebook analyst commentary  »

Facebook survey suggests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 07

    Nov

UBS

UBS

$16.40

-0.125 (-0.76%)

07:26
09/25/18
09/25
07:26
09/25/18
07:26
Conference/Events
UBS management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

07:26
09/25/18
09/25
07:26
09/25/18
07:26
General news
Futures higher in rebound from yesterday's selloff »

Stock futures are…

WELL

Welltower

$63.98

-1.525 (-2.33%)

07:26
09/25/18
09/25
07:26
09/25/18
07:26
Initiation
Welltower initiated  »

Welltower initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Oct

SQ

Square

$86.06

0.75 (0.88%)

07:25
09/25/18
09/25
07:25
09/25/18
07:25
Conference/Events
Square management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 26

    Nov

07:25
09/25/18
09/25
07:25
09/25/18
07:25
General news
FX Update: The euro traded firmer »

FX Update: The euro…

BYSI

BeyondSpring

$25.42

0.02 (0.08%)

07:24
09/25/18
09/25
07:24
09/25/18
07:24
Hot Stocks
BeyondSpring presents clinical data showing Plinabulin reduces thrombocytopenia »

BeyondSpring presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PINC

Premier

$43.76

0.25 (0.57%)

07:23
09/25/18
09/25
07:23
09/25/18
07:23
Initiation
Premier initiated  »

Premier initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$90.96

3.4 (3.88%)

07:21
09/25/18
09/25
07:21
09/25/18
07:21
Conference/Events
Reata Pharmaceuticals to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 01

    Oct

OIBR

Oi S.A.

$0.00

(0.00%)

07:21
09/25/18
09/25
07:21
09/25/18
07:21
Downgrade
Oi S.A. rating change  »

Oi S.A. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RETA

Reata Pharmaceuticals

$90.96

3.4 (3.88%)

07:21
09/25/18
09/25
07:21
09/25/18
07:21
Hot Stocks
Reata Pharmaceuticals T1D CKD cohorts of PHOENIX trial meet endpoint »

Reata Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SB

Safe Bulkers

$2.72

-0.01 (-0.37%)

07:19
09/25/18
09/25
07:19
09/25/18
07:19
Conference/Events
Safe Bulkers management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 08

    Oct

HEP

Holly Energy Partners

$32.95

0.43 (1.32%)

07:19
09/25/18
09/25
07:19
09/25/18
07:19
Downgrade
Holly Energy Partners rating change  »

Holly Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

KORS

Michael Kors

$66.71

-5.96 (-8.20%)

07:18
09/25/18
09/25
07:18
09/25/18
07:18
Hot Stocks
Michael Kors sees opportunity to grow revenues to $8B in long-term »

In slides being presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$73.59

-0.11 (-0.15%)

, AAPL

Apple

$220.79

3.14 (1.44%)

07:17
09/25/18
09/25
07:17
09/25/18
07:17
Recommendations
Qualcomm, Apple analyst commentary  »

Qualcomm estimates…

QCOM

Qualcomm

$73.59

-0.11 (-0.15%)

AAPL

Apple

$220.79

3.14 (1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

CLX

Clorox

$149.98

-2.34 (-1.54%)

07:17
09/25/18
09/25
07:17
09/25/18
07:17
Upgrade
Clorox rating change  »

Clorox upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVAX

Novavax

$1.84

0.24 (15.00%)

07:17
09/25/18
09/25
07:17
09/25/18
07:17
Hot Stocks
Novavax initiates Phase 2 trial of NanoFlu in older adults »

Novavax announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 27

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.